Cardiac oncostatin M (Osm) induces dedifferentiation of cardiomyocytes and promotes progression of HF, and an antibody targeting Oβ or genetic inactivation of a single allele of Osmr reduces cardiomyocyte remodelling and dedifferentiation and improves cardiac performance and survival (Kubin et al., 2011; Pöling et al., 2013). This evidence concerns the gene OSM and hydrops fetalis.